This Dow Jones headline alone would send seismic tremors in the CV world!!
Its worth noting that from Novartis' perspective, paraphrasing @The Yankee...
Think about how perfectly Entresto would complement MESO's Revascor. This would make for a perfect end-to-end treatment in heart disease. Now throw in their recent purchase of the LDL-C reducing drug Inclisiran and you have just found your "one stop shop " in an incredibly powerful combination treatment for the number one killer in the world - heart disease.
If I were Novartis, I would be revising my cheque for the upfront payment and terms of the partnership to now include Revascor in the mix.
This Dow Jones headline alone would send seismic tremors in the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |